Skip to main content
PMC home page
Cell Proliferation logoLink to Cell Proliferation
. 2019 Oct 22;53(1):e12709. doi: 10.1111/cpr.12709

CRYAB promotes osteogenic differentiation of human bone marrow stem cells via stabilizing β‐catenin and promoting the Wnt signalling

Bin Zhu 1, Feng Xue 1, Guangyi Li 1,✉, Changqing Zhang 1,✉
PMCID: PMC6985673  PMID: 31638302

Abstract

Objectives

The osteogenesis differentiation of human bone marrow stem cells (BMSCs) is essential for bone formation and bone homeostasis. In this study, we aim to elucidate novel molecular targets for bone metabolism diseases.

Materials and methods

The dataset GSE80614 which includes mRNA expression profile during BMSCs osteogenic differentiation was obtained from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). The osteogenic differentiation of BMSCs was measured by ALP staining, AR staining and expression of osteogenic markers in vitro. For in vivo assay, we seeded BMSCs onto beta‐tricalcium phosphate (β‐TCP) and transplanted them into muscle pockets of nude mice. Luciferase assay, co‐immunoprecipitation assay and in vitro ubiquitination assay were carried out to investigate the molecular mechanism.

Results

We found that α‐B‐crystallin (CRYAB) expression was elevated during the process of BMSCs osteogenic differentiation. Further studies showed that upregulation of CRYAB significantly enhanced the osteogenic differentiation, while downregulation of CRYAB suppressed it. CRYAB regulated BMSCs osteogenic differentiation mainly through the canonical Wnt/β‐catenin signalling. In addition, we found that CRYAB could physically interact with β‐catenin and protect it from ubiquitination and degradation, which stabilized β‐catenin and promoted the Wnt signalling.

Conclusions

The present study provides evidences that CRYAB is an important regulator of BMSCs osteogenic differentiation by protecting β‐catenin from ubiquitination and degradation and promoting the Wnt signalling. It may serve as a potential therapeutic target for diseases related to bone metabolism.

Keywords: bone, CRYAB, osteogenic differentiation, Wnt/β‐catenin signaling

1. INTRODUCTION

Human bone marrow stem cells (BMSCs) exhibit great capacity to differentiate into numerous mature cell types under the guidance of several factors including microenvironment, molecular and genetic mediators.1, 2, 3 Osteoblasts, as one of the products of BMSCs differentiation, play a key role in bone formation and bone homeostasis.4, 5, 6 The dysfunction of BMSCs osteogenic differentiation will lead to bone metabolism‐related diseases.7, 8 Thus, it is crucial to elucidate the underlying mechanism of BMSCs osteogenic differentiation.

Canonical Wnt signalling has been revealed to be critical in maintaining homeostasis and embryonic development in human.9, 10, 11 The transduction of Wnts signals through the plasma membrane relies on the frizzled protein, which is a member of G protein‐coupled receptors family.12, 13 When the Wnt ligands are absent, a multiprotein complex is composed by β‐catenin, AXIN, adenomatous polyposis coli (APC), glycogen synthase kinase 3β and casein kinase 1. In the presence of Wnt ligands, the protein complex is phosphorylated and decomposed, and β‐catenin is released. Then, the released β‐catenin is transferred into the nucleus and combines with T‐cell factor/lymphoid enhancer factor (TCF/LEF) to start the following transcriptional activities.14, 15 Increasing studies have demonstrated that the canonical Wnt/β‐catenin pathway is vital to osteogenic differentiation of BMSCs and bone metabolism.16, 17, 18

The ubiquitin‐proteasome system is essential for the elimination of several short‐lived proteins. Commonly, targeted proteins are labelled by ubiquitin molecules through a sequence of enzymatic reactions, including E1 (ubiquitin‐activating enzymes), E2 (ubiquitin‐conjugation enzymes) and E3 (ubiquitin ligases), and are eventually degraded into peptides by proteasomes. Evidences have verified that β‐catenin, a key factor of Wnt/β‐catenin signalling pathway, is also a target for the ubiquitin‐proteasome system, and that the degradation of β‐catenin directed by ubiquitin‐proteasome system plays important roles in tumour suppression,19, 20, 21 bone marrow stem cell osteogenic differentiation,22, 23 et al

α‐B‐crystallin (CRYAB) has been reported as a major structural protein of the eye lens and is abundant in kidney, central nervous system, skeletal muscle and heart.24, 25 As a member of the small heat‐shock protein (sHSP) family, CRYAB plays important roles in cellular development, differentiation and apoptosis inhibition.26, 27, 28 In addition, CRYAB also acts as a molecular chaperone and functions in the recognition, binding and refolding of several unfolded proteins, and protects them from degradation.29, 30 In this study, we discovered that the CRYAB expression is gradually increased in BMSCs during the osteogenic differentiation process. Further experiments revealed that CRYAB exhibits a promotion effect on BMSCs osteogenic differentiation both in vitro and in vivo. In addition, we demonstrated that CRYAB could regulate the Wnt/β‐catenin signalling by protecting β‐catenin from ubiquitination and degradation. In summary, these findings indicate that CRYAB acts as a regulator of BMSCs osteogenic differentiation and may serve as an underlying therapeutic target for diseases related to bone homeostasis.

2. MATERIALS AND METHODS

2.1. Microarray analysis

The mRNA expression profile during osteogenic differentiation process of human bone marrow stem cells was included in the dataset GSE80614. We obtained the dataset from the GEO database (https://www.ncbi.nlm.nih.gov/geo/) and analysed the differentially expressed mRNAs at different time points (3 and 4 days vs 1 and 2 hours). |logFC| > 2 and P‐value < .01 was set as threshold.

2.2. Cell culture

Human bone marrow stem cells (BMSCs) were got from a 43‐year‐old donor who suffered an severe trauma and underwent amputation and were maintained in α‐modified essential medium (α‐MEM; Sigma‐Aldrich) that contained 10% foetal bovine serum (FBS) (Gibco) and 100 µg/mL penicillin‐streptomycin sulphate (Sigma‐Aldrich) at 37°C in a 5% CO2 humidified incubator.

2.3. In vitro differentiation assays

For the in vitro adipogenic and osteogenic differentiation assays, BMSCs were treated with adipogenic differentiation medium (Cyagen) or osteogenic differentiation medium (Cyagen) follow the operating instruction in 24‐well plates for 7 or 14 days. The differentiation medium was refreshed every 2 days. Oil Red O staining, Western blot and qRT‐PCR were used to measure the adipogenic differentiation efficacy. Alizarin red (AR) staining, alkaline phosphatase (ALP) staining, Western blotting and qRT‐PCR were used to measure the osteogenic differentiation efficacy.

2.4. RNA isolation and qRT‐PCR assays

The isolation of total RNA from BMSCs was performed using TRIzol reagents (Invitrogen) and isolated the total RNA was then quantified using Nanodrop 2000 (Thermo). The PrimerScriptRT Reagent (TaKaRa) was used according to the operating instruction for reverse‐transcription of cDNA. The reactions of real‐time PCR were performed with the aid of SYBR Green kit (TaKaRa) using ABI HT7900 (Applied Biostralia). The gene expression levels were normalized to β‐actin. Primer sequences are listed in Table S1.

2.5. Western blot analysis and Co‐immunoprecipitation

Cells were lysed in Cell Lysis Buffer (Sigma‐Aldrich) on ice and denatured by heating at 95°C for 15 minutes with the addition of loading buffer (BioTNT). The samples were separated using a 10% SDS‐PAGE gel (EpiAyme) by electrophoresis at 120 V for 75 minutes. Then, the proteins were transferred through electroblotting at 280 mA for 70 minutes to a PVDF membrane (Millipore). After blocking in 5% non‐fat milk for 60 minutes, the membrane was incubated with primary antibodies at 4°C for 12 hours, followed by incubation with the secondary antibody at room temperature for 1 hour. Image Quant LAS 4000 (GE Healthcare) was used to confirm the expression levels of proteins. The expression of β‐actin was used as control.

An immunoprecipitation kit (Abcam) was used for co‐immunoprecipitation assay according to the operating instruction. Briefly, lysis buffer was pre‐cooled on ice and the Protease Inhibitor Cocktail was added for the preparation of cell lysis. The supernatant of the cell lysis was collected after centrifuged at 1000 g for 15 minutes, and the primary antibodies were added and incubated at 4°C for one night. Then, the Protein A/G Sepharose beads were added and incubated at 4°C for 1 hour and then separated by centrifugation at low speed. The beads were washed for three times and the precipitated proteins were eluted followed by Western blotting analysis.

The antibodies are listed in Table S2.

2.6. Plasmid transfection and reporter gene activity assay

For siRNA transfection, Lipofectamine 2000 (Invitrogen, California, USA) was used according to the manufacturer's instructions and the cells were collected to assess the efficacy of transfection by qRT‐PCR or Western blotting 24 hours later. For virus productions, 293T cells were transfected with 3.6 µg envelope plasmid, 9 µg packaging plasmid and 12 µg targeting plasmids using Lipofectamine 2000, and the viruses were harvested and filtered 48 hours later. The infection of BMSCs was performed with the addition of polybrene follow the operating instruction. For TOPFlash reporter assay, 293T cells were transfected with β‐galactosidase, CRYAB‐specific siRNA or corresponding control siRNA and Super (8×) TOPFlash plasmid using Lipofectamine 2000. Serum starvation was performed for overnight 24 hours after the transfection, and the osteogenic differentiation medium was then used for cell culture. The cells were lysed 48 hours later and a luciferase assay system (Promega) was used to measure the luciferase activity.

2.7. In vitro ubiquitination assay

Cells were lysed using cell lysis buffer after treated with a proteasome inhibitor, MG 132, for 8 hours, and the lysis was incubated with antibodies for 3 hours at 4°C. Then the Sepharose beads of protein A/G were added to the lysis and rotated gently for 10 hours at 4°C. The beads were collected and washed three times with centrifugation at low speed. The SDS‐loading buffer was used to elute the immunoprecipitated proteins at 95°C for 3 hours, and Western blotting assay was applied for analysis.

2.8. Animal studies

Eight‐week‐old male nude mice were employed for animal studies in this experiment, and all of these mice were kept in a specific‐pathogen‐free condition. Beta‐tricalcium phosphate (β‐TCP; Bio‐lu, 5 × 5 × 3 mm) with BMSCs (5 × 106) seeded on was transplanted and buried into muscle pockets on the posterior limb of the mice. Forty‐two mice were divided into seven groups, namely sh‐Control group, sh‐CRYAB group, Vector group, CRYAB group, sh‐Control + Vector group, sh‐CRYAB + Vectro group and sh‐CRYAB + β‐catenin group. Corresponding kind of BMSCs was used in each group. The mice were put to death 8 weeks later, and the transplants were collected from the posterior limbs for histological analysis. 10% EDTA was used to decalcify the transplants after fixation in 10% formalin for 3 days. The samples were then sliced using Leica RM2235 for H&E (Haematoxylin and Eosin) staining. BIOQUANT OSTEO software (BIOQUANT) was used to collect the images. All experiments were subject to approval by the Ethics Committee of Shanghai Sixth People's Hospital.

2.9. Statistical analysis

All results were replicated independently for three times. SPSS 16.0 (IBM Corporation) was used to complete the statistical analysis. Two‐tailed Student's t test was used to evaluate the statistical differences between two groups, and one‐way analysis of variance (ANOVA) was used to evaluate the statistical differences among more than two groups. Values of P < .05 were considered statistically significant. All values are presented as means ± SD (standard deviation).

3. RESULTS

3.1. CRYAB expression is upregulated during the process of BMSCs osteogenic differentiation

In the present study, the dataset GSE80614 was analysed to explore the differentially expressed genes at different time points during BMSCs osteogenic differentiation process. A total of 109 differentially expressed genes (including 52 downregulated genes and 57 upregulated genes) were identified when comparing the differentiation time of 3 or 4 days to that of 1 or 2 hours (Figure 1A). The bioinformatics analysis of these differentially expressed genes is shown in Figure S1. Then, eight downregulated genes and 25 upregulated genes were chosen to further validate the dataset. As determined by qRT‐PCR analysis, the expression of these genes was consistent with the dataset (Figure 1B and C). Previous studies have reported several of the above‐mentioned genes (CIDEC, MAOA, SAA1, SVEP1, FBLN2, ADARB1, ZBTB16, ANGPT1, FBLN1, FZD4, OMD, ABI3BP, RGS4, CXCL8) are closely related to bone homeostasis and the process of osteogenic differentiation,31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 and these studies further supported the reliability of the dataset. To identify the BMSCs osteogenic differentiation‐related genes, we chose 10 of the other upregulated genes, namely EFHD1, FKBP5, APOD, ACTC1, SORT1, COMP, CLEC3B, CRYAB, WASF3, LMOD1, and downregulated their expression by specific siRNA in BMSCs (Figure 1D‐M). The results showed that the downregulation of CRYAB expression significantly impaired the capacity of BMSCs osteogenic differentiation as determined by ALP activity (Figure 1N). Furthermore, we also detected the CRYAB protein expression level and found that it was gradually increased along with the course of osteogenic differentiation (Figure 1O). Therefore, we speculated that CRYAB might play a critical role in human BMSCs osteogenic differentiation process.

Figure 1.

Figure 1

Open in a new tab

CRYAB expression is upregulated during the process of BMSCs osteogenic differentiation. A, A total of 109 differentially expressed genes (52 downregulated genes and 57 upregulated genes) were identified when comparing the differentiation time of 3 or 4 d to that of 1 or 2 h. B&C, Eight downregulated genes and twenty‐five upregulated genes were chosen to further validate the dataset using qRT‐PCR. D‐M, Ten upregulated genes were chosen for functional screen in BMSCs and their expression were downregulated using specific siRNA. N, ALP activity was measured after BMSCs were treated with specific siRNA. O, The expression of CRYAB in BMSCs was measured using Western blotting during the process of osteogenic differentiation

3.2. The role of CRYAB in osteogenic differentiation in vitro

To verify our speculation about the role of CRYAB in the process of human BMSCs osteogenic differentiation, we knocked down its expression using a specific shRNA and evaluated the change of osteogenic differentiation capacity using ALP staining at day 7 and alizarin red staining at day 14 (Figure 2A and B). We found that knocking‐down of CRYAB expression significantly inhibited the capacity of BMSCs osteogenic differentiation as evaluated by ALP and AR staining (Figure 2C). We also found that the mRNA and protein expression levels of osteogenic markers, including COL1A1, ALP, RUNX2, SP7, OCN and OPN, were inhibited by knocking‐down of CRYAB expression (Figure 2D and E). Additionally, we also upregulated the CRYAB expression in human BMSCs using specific lentivirus in order to further confirm its role in osteogenic differentiation. Western blotting and qRT‐PCR were used to assess the efficacy of lentivirus (Figure 2F and G), and ALP staining and AR staining were used to assess the capacity of osteogenic differentiation. We found that upregulation of CRYAB expression significantly enhanced the capacity of BMSCs osteogenic differentiation as evaluated by ALP and AR staining (Figure 2H). Additionally, the mRNA and protein expression levels of osteogenic markers, including COL1A1, ALP, RUNX2, SP7, OCN and OPN, were increased by upregulation of CRYAB expression (Figure 2I and J).

Figure 2.

Figure 2

Open in a new tab

The role of CRYAB in osteogenic differentiation in vitro. A&B, qRT‐PCR and Western blotting were used to determine the efficacy of CRYAB‐specific shRNA. C, The osteogenic capacity of CRYAB‐downregulated BMSCs was measured by alizarin red staining and ALP staining at day 14 or day 7 after treated with osteogenic induction media. D, The expression of osteogenic markers at mRNA level was measured by qRT‐PCR. E, The expression of osteogenic markers at protein level was measured by Western blotting. F&G, qRT‐PCR and Western blotting were used to determine the efficacy of CRYAB‐specific lentivirus. H, The osteogenic capacity of CRYAB‐upregulated BMSCs was measured by alizarin red staining and ALP staining at day 14 or day 7 after treated with osteogenic induction media. I, The expression of osteogenic markers at mRNA level was measured by qRT‐PCR. J, The expression of osteogenic markers at protein level was measured by Western blotting

3.3. The function of CRYAB in osteogenic differentiation in vivo

In vivo experiments were performed to further confirm our in vitro findings. BMSCs treated with CRYAB‐specific shRNA or lentivirus to stably down‐ or upregulate its expression were loaded on shaped β‐TCP (tricalcium phosphate), followed by transplantation into muscle pockets on the posterior limb of nude mice. The mice were put to death 8 weeks later, and the transplants were collected from the posterior limbs for histological analysis. We found that less bone tissue was formed in the CRYAB‐downregulated group when compared with the control group (Figure 3A and B), while more bone tissue was formed in the CRYAB‐upregulated group when compared with its control group (Figure 3C and D). Furthermore, we could also find that downregulation of CRYAB expression increased the formation of adipose tissue while upregulation of CRYAB expression decreased the formation of adipose tissue in H&E staining (Figure 3A and C). Therefore, we hypothesized that CRYAB might also play a critical role in human BMSCs adipogenic differentiation.

Figure 3.

Figure 3

Open in a new tab

The function of CRYAB in osteogenic differentiation in vivo. A, Representative images of H&E staining of transplants in the sh‐CRYAB group and sh‐Control group. The new formed bone was denoted by black arrows. Scale bar represents 100 µm. B, The bone formation was measured qualitatively. C, Representative images of H&E staining of transplants in the CRYAB group and Vector group. The new formed bone was denoted by black arrows. Scale bar represents 100 µm. D, The bone formation was measured qualitatively. E&F, Representative images of Oil Red O staining in different groups after BMSCs were treated for 14 d with adipogenic induction medium. G&H, The qRT‐PCR was used to measure the expression of PPARG in BMSCs at mRNA level during the adipogenic differentiation process. I&J, The Western blotting was used to measure the expression of PPARG in BMSCs at protein level at day 15 of the adipogenic differentiation

To further verify our hypothesis, we assessed the adipogenic differentiation efficacy of BMSCs using Oil Red O staining and qRT‐PCR assays after the cells were treated with adipogenic induction medium. It was demonstrated that the adipogenesis of BMSCs was enhanced by downregulating CRYAB expression (Figure 3E), while reduced by upregulating CRYAB expression (Figure 3F). And the downregulation of CRYAB expression significantly enhanced the expression of adipogenic markers, PPARG, CEBPA and ADIPOQ, while the upregulation of CRYAB expression reduced them (Figure 3G‐J, Figure S2).

3.4. CRYAB regulates the BMSCs osteogenic differentiation via the WNT signalling

The canonical Wnt signalling has been proven to be vital for human bone homeostasis and human BMSCs osteogenic differentiation. To explore whether CRYAB influenced the process of osteogenesis through the Wnt signalling, we firstly measured the expression of β‐catenin, a core element of the Wnt/β‐catenin pathway. We found that the downregulation of CRYAB expression significantly decreased β‐catenin protein level as measured by Western blotting, and upregulation of CRYAB expression increased it (Figure 4A and C). However, the alteration of CRYAB expression hardly influenced the β‐catenin mRNA level as measured by qRT‐PCR (Figure 4B and D). In addition, the phosphorylation level of β‐catenin was increased by downregulation of CRYAB, and decreased by upregulation of CRYAB (Figure 4A and C). Besides, we found that the upregulation of CRYAB promoted the nuclear accumulation of β‐catenin, and the downregulation of CRYAB suppressed it (Figure 4E and G). Then, we measured the GSK‐3β phosphorylation level at Ser9, which is a vital step for the activation of canonical Wnt signalling.45, 46 We found that the expression level of GSK‐3β phosphorylated at Ser9 was reduced by downregulation of CRYAB expression and elevated by upregulation of CRYAB expression, while the total GSK‐3β levels almost kept the same (Figure 4A and C). In addition, we employed the TOPFlash reporter assay to further assess the effect of CRYAB on the Wnt signalling in 293T cell line. As we have shown in Figure 4F and H, the luciferase activity was significantly increased by upregulation of CRYAB and decreased by downregulation of CRYAB. To further confirm the effect of CRYAB on the Wnt signalling, we determined the regulation effect of CRYAB on the Wnt signalling target genes, including AXIN2 and LEF1. As measured by qRT‐PCR, the mRNA expression of these target genes was upregulated by the upregulation of CRYAB expression, and downregulated by the downregulation of CRYAB expression (Figure 4I‐L). The results were also confirmed in protein level by Western blotting (Figure 4A and C). Besides, as determined by ALP and AR staining, the enhanced osteogenic capacity of BMSCs resulting from the upregulation of CRYAB expression was reduced by the treatment with ICG‐001, an inhibitor of the Wnt signalling; and the restricted osteogenic capacity of BMSCs resulting from the downregulation of CRYAB expression was rescued by the treatment with Wnt3a, an activator of the Wnt signalling (Figure 4M and N).

Figure 4.

Figure 4

Open in a new tab

CRYAB regulates the BMSCs osteogenic differentiation via the WNT signalling. A, The expression of GSK‐3β, p‐GSK‐3β (Ser9), β‐catenin, p‐β‐catenin (Ser33/37/Thr41), LEF1 and AXIN2 at protein level in sh‐CRYAB group and sh‐Control group was measured by Western blotting. B, The expression of CTNNB1 at mRNA level in sh‐CRYAB group and sh‐Control group was measured by qRT‐PCR. C, The expression of GSK‐3β, p‐GSK‐3β (Ser9), β‐catenin, p‐β‐catenin (Ser33/37/Thr41), LEF1 and AXIN2 at protein level in CRYAB group and Vector group was measured by Western blotting. D, The expression of CTNNB1 at mRNA level in CRYAB group and Vector group was measured by qRT‐PCR. E, The expression of nuclear β‐catenin at protein level in sh‐CRYAB group and sh‐Control group was measured by Western blotting. F, Relative TOPFlash luciferase activity was measured in sh‐CRYAB group and sh‐Control group. G, The expression of nuclear β‐catenin at protein level in CRYAB group and Vector group was measured by Western blotting. H, Relative TOPFlash luciferase activity was measured in CRYAB group and Vector group. I‐L, The expression of AXIN2 and LEF1 at mRNA level was measured by qRT‐PCR. M, AR staining and ALP staining showed that the restricted osteogenic capacity of BMSCs resulting from the downregulation of CRYAB expression was rescued by the treatment with Wnt3a. N, AR staining and ALP staining showed that the enhanced osteogenic capacity of BMSCs resulting from the upregulation of CRYAB expression was reduced by the treatment with ICG‐001

3.5. CRYAB is essential for β‐catenin stabilization

The ubiquitin‐proteasome system has been verified to play essential roles in regulating the stability, subcellular localization and activity of proteins. Since the alteration of CRYAB expression significantly influenced the protein level of β‐catenin without changing its mRNA level (Figure 4A‐D), we speculated that the degradation of β‐catenin by the ubiquitin‐proteasome system may be influenced by CRYAB. To verify our speculation, the co‐immunoprecipitation assay was carried out and we found that CRYAB could physically interact with β‐catenin in human BMSCs (Figure 5C). The ubiquitination of β‐catenin was examined in BMSCs after treatment with a proteasome inhibitor, MG132, for 8 hours. We found that the ubiquitination level of β‐catenin was enhanced by the downregulation of CRYAB and reduced by the upregulation of CRYAB (Figure 5A and B). In addition, the stability of β‐catenin was determined after BMSCs were treated with a protein synthesis inhibitor, cycloheximide (CHX), for indicated hours. We found that the downregulation of CRYAB significantly reduced the half‐life of β‐catenin (Figure 5D and E).

Figure 5.

Figure 5

Open in a new tab

CRYAB is essential for β‐catenin stabilization. A&B, The ubiquitination level of β‐catenin was enhanced by the downregulation of CRYAB and reduced by the upregulation of CRYAB. C, CRYAB could physically interact with β‐catenin in human BMSCs as determined by co‐immunoprecipitation. D&E, The stability of β‐catenin was determined after BMSCs were treated with a protein synthesis inhibitor, cycloheximide (CHX), for indicated hours. F, Representative images of H&E staining of transplants from different groups. The new formed bone was denoted by black arrows. Scale bar represents 100 µm. G, The bone formation was measured qualitatively

Besides, CRYAB‐downregulated BMSCs were transfected with β‐catenin‐lentivirus or the corresponding control lentivirus, and the cells were loaded on β‐TCP and transplanted into muscle pockets on the posterior limb of nude mice. Eight weeks later, the mice were put to death and the transplants were harvested for histological analysis. As shown in Figure 5F and G, the overexpression of β‐catenin could rebuild the osteogenic differentiation capacity of CRYAB‐downregulated BMSCs.

Additionally, the regulatory network of CRYAB on the osteogenic differentiation of BMSCs is shown in Figure 6.

Figure 6.

Figure 6

Open in a new tab

CRYAB promotes osteogenic differentiation of human bone marrow stem cells via stabilizing β‐catenin and promoting the Wnt signalling

4. DISCUSSION

Bone is a metabolically active organ of human and is continuously remodelled via the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts.47, 48 The dysfunction of osteoblasts, which are the products of BMSCs osteogenic differentiation, may induce a decline in bone formation and an imbalance of bone homeostasis, and it may eventually cause bone metabolism‐related diseases.49, 50 Thus, it is necessary to figure out the molecular mechanism involved in BMSCs osteogenic differentiation, which may provide us potential targets for the improvement of therapeutic approaches for bone metabolism‐related diseases.

Total mRNA expression of human BMSCs cultured in osteogenic differentiation medium was measured at different time points by van de Peppel J. and his colleagues, and the mRNA expression profile was included in the dataset GSE80614.51 We studied this dataset in the current research by comparing the expression profiles of BMSCs (3 & 4 days vs 1 & 2 hours) and identified 52 downregulated and 57 upregulated genes. Twenty‐five upregulated and eight downregulated genes were selected to examine the reliability of the microarray. The reliability of the dataset was further verified given that several of the selected genes have been assessed before and were proven to be strongly linked to osteogenic differentiation of BMSCs and bone homeostasis.31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 Then, functional screen was performed by ALP activity assays after target genes were knocked down by specific siRNA. We found that the ALP activity was significantly reduced by the downregulation of CRYAB expression in BMSCs. These findings revealed that CRYAB plays a role in the osteogenic differentiation of BMSCs.

As a member of the small heat‐shock protein family, CRYAB possesses several important roles. In cardiomyocytes and vascular endothelial cells, CRYAB has been shown to exhibit a protective role against apoptosis.52, 53, 54, 55 The expression of CRYAB has also been proven to be closely related to neurological diseases, including Alexander's disease, Parkinson's disease and Alzheimer's disease.56, 57, 58 In addition, CRYAB is deemed as an oncogenic gene for its protection effect on cancer cells from chemotherapeutic drugs.54, 59 Previous studies on mass spectrum and oligonucleotide microarrays also found an alteration of CRYAB expression level during osteogenic differentiation of human BMSCs, which is consistent with our findings from the dataset http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80614.60, 61 However, the exact role of CRYAB on osteogenic differentiation of BMSCs has seldomly been studied. To further explore the role of CRYAB on osteogenic differentiation of BMSCs, we performed in vitro and in vivo studies. In the in vitro study, we discovered that the expression level of CRYAB in BMSCs was closely related with their capacity of osteogenesis as measured by alizarin red staining and ALP staining. In vivo experiments using a BMSCs‐transplantation assay in nude mice further confirmed the observation. Furthermore, we found an inverse relationship between the expression of CRYAB and the capability of BMSCs adipogenic differentiation. These findings manifest that CRYAB is essential for BMSCs osteogenic differentiation.

The canonical Wnt/β‐catenin signalling has been verified to exhibit a vital effect on BMSCs osteogenic differentiation and bone metabolism.62, 63 Kuci S and his colleagues noticed that the expression of CRYAB and the activity of Wnt signalling were both increased during the osteogenic differentiation process of BMSCs.64 In this study, we found that the Wnt/β‐catenin signalling was also crucial for the CRYAB‐regulated osteogenic differentiation of BMSCs. Since β‐catenin is a core component of the Wnt/β‐catenin signalling and acts a core function of this pathway,65 we further explored the relationship of CRYAB and β‐catenin. We found that CRYAB could physically interact with β‐catenin and protect it from ubiquitination and degradation.

In conclusion, we found that the expression of CRYAB is upregulated in the osteogenic differentiation process of BMSCs. CRYAB acts as a regulator of BMSCs osteogenic differentiation, and the regulatory effect is achieved by stabilizing β‐catenin and regulating the Wnt signalling. These findings illustrate that CRYAB might be a new regulator of BMSCs osteogenic differentiation and may serve as an underlying therapeutic target for diseases related to bone homeostasis.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Supporting information

 

Click here for additional data file. (365.6KB, docx)

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Fund of China (81702181), Shanghai Pujiang Talent Program (16PJ1408100), and Clinical Skills Upgrading Program for Major Diseases (16CR1038B).

Zhu B, Xue F, Li G, Zhang C. CRYAB promotes osteogenic differentiation of human bone marrow stem cells via stabilizing β‐catenin and promoting the Wnt signalling. Cell Prolif. 2020;53:e12709 10.1111/cpr.12709

Bin Zhu and Feng Xue contributed equally to this work.

Funding information

This work was supported by the National Natural Science Fund of China (81702181), Shanghai Pujiang Talent Program (16PJ1408100), and Clinical Skills Upgrading Program for Major Diseases (16CR1038B).

Contributor Information

Guangyi Li, Email: guangyi.li@shsmu.edu.cn.

Changqing Zhang, Email: zhangcq@sjtu.edu.cn.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available in GEO database at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80614.66

REFERENCES

  • 1. Chen X, Zhi X, Wang J, Su J. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation. Bone Res. 2018;6:34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Liu W, Zhang L, Xuan K, et al. Alpl prevents bone ageing sensitivity by specifically regulating senescence and differentiation in mesenchymal stem cells. Bone Res. 2018;6:27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ren K, Cui H, Xu Q, He C, Li G, Chen X. Injectable polypeptide hydrogels with tunable microenvironment for 3D spreading and chondrogenic differentiation of bone‐marrow‐derived mesenchymal stem cells. Biomacromol. 2016;17(12):3862‐3871. [DOI] [PubMed] [Google Scholar]
  • 4. Horsnell H, Baldock PA. Osteoblastic actions of the neuropeptide y system to regulate bone and energy homeostasis. Curr Osteoporos Rep. 2016;14(1):26‐31. [DOI] [PubMed] [Google Scholar]
  • 5. Ye L, Lou F, Yu F, et al. NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts. Bone Res. 2018;6:32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Xu Z, Greenblatt MB, Yan G, et al. SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblasts. Nat Commun. 2017;8:14570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wu Y, Xie L, Wang M, et al. Mettl3‐mediated m(6)A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun. 2018;9(1):4772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Li CJ, Xiao Y, Yang M, et al. Long noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal aging. J Clin Invest. 2018;128(12):5251‐5266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Chae WJ, Bothwell A. Canonical and non‐canonical Wnt signaling in immune cells. Trends Immunol. 2018;39(10):830‐847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Clevers H, Nusse R. Wnt/beta‐catenin signaling and disease. Cell. 2012;149(6):1192‐1205. [DOI] [PubMed] [Google Scholar]
  • 11. Wang Y, Zhou CJ, Liu Y. Wnt Signaling in kidney development and disease. Prog Mol Biol Transl Sci. 2018;153:181‐207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Range RC. Canonical and non‐canonical Wnt signaling pathways define the expression domains of Frizzled 5/8 and Frizzled 1/2/7 along the early anterior‐posterior axis in sea urchin embryos. Dev Biol. 2018;444(2):83‐92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Schulte G, Wright SC. Frizzleds as GPCRs ‐ more conventional than we thought!. Trends Pharmacol Sci. 2018;39(9):828‐842. [DOI] [PubMed] [Google Scholar]
  • 14. Tolwinski NS, Wehrli M, Rives A, Erdeniz N, DiNardo S, Wieschaus E. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev Cell. 2003;4(3):407‐418. [DOI] [PubMed] [Google Scholar]
  • 15. Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the beta‐catenin pathway by forming oligomers containing its receptors. Frizzled and LRP. Development. 2004;131(20):5103‐5115. [DOI] [PubMed] [Google Scholar]
  • 16. Zhang J, Zhang X, Zhang L, Zhou F, van Dinther M, Ten Dijke P. LRP8 mediates Wnt/beta‐catenin signaling and controls osteoblast differentiation. J Bone Miner Res. 2012;27(10):2065‐2074. [DOI] [PubMed] [Google Scholar]
  • 17. Rossini M, Gatti D, Adami S. Involvement of WNT/beta‐catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121‐132. [DOI] [PubMed] [Google Scholar]
  • 18. Milat F, Ng KW. Is Wnt signalling the final common pathway leading to bone formation? Mol Cell Endocrinol. 2009;310(1–2):52‐62. [DOI] [PubMed] [Google Scholar]
  • 19. Xue J, Chen Y, Wu Y, et al. Tumour suppressor TRIM33 targets nuclear beta‐catenin degradation. Nat Commun. 2015;6:6156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Wu H, Lu XX, Wang JR, et al. TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/beta‐catenin degradation and is targeted for GSK3B/GSK3beta‐mediated phosphorylation and degradation. Autophagy. 2019;15(9):1506‐1522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Novellasdemunt L, Foglizzo V, Cuadrado L, et al. USP7 is a tumor‐specific WNT activator for APC‐mutated colorectal cancer by mediating beta‐catenin deubiquitination. Cell Rep. 2017;21(3):612‐627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Greenblatt MB, Shin DY, Oh H, et al. MEKK2 mediates an alternative beta‐catenin pathway that promotes bone formation. Proc Natl Acad Sci U S A. 2016;113(9):E1226‐1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Chang J, Liu F, Lee M, et al. NF‐kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta‐catenin degradation. Proc Natl Acad Sci U S A. 2013;110(23):9469‐9474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Lu SZ, Guo YS, Liang PZ, et al. Suppression of astrocytic autophagy by alphaB‐crystallin contributes to alpha‐synuclein inclusion formation. Transl Neurodegener. 2019;8:3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Andley UP. Crystallins in the eye: function and pathology. Prog Retin Eye Res. 2007;26(1):78‐98. [DOI] [PubMed] [Google Scholar]
  • 26. Andley UP. Effects of alpha‐crystallin on lens cell function and cataract pathology. Curr Mol Med. 2009;9(7):887‐892. [DOI] [PubMed] [Google Scholar]
  • 27. Rauch JN, Tse E, Freilich R, et al. BAG3 is a modular, scaffolding protein that physically links heat shock protein 70 (Hsp70) to the small heat shock proteins. J Mol Biol. 2017;429(1):128‐141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Acunzo J, Katsogiannou M, Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB‐crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol. 2012;44(10):1622‐1631. [DOI] [PubMed] [Google Scholar]
  • 29. Ghosh JG, Shenoy AK Jr, Clark JI. Interactions between important regulatory proteins and human alphaB crystallin. Biochemistry. 2007;46(21):6308‐6317. [DOI] [PubMed] [Google Scholar]
  • 30. Kase S, He S, Sonoda S, et al. alphaB‐crystallin regulation of angiogenesis by modulation of VEGF. Blood. 2010;115(16):3398‐3406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Meyer MB, Benkusky NA, Sen B, Rubin J, Pike JW. Epigenetic plasticity drives adipogenic and osteogenic differentiation of marrow‐derived mesenchymal stem cells. J Biol Chem. 2016;291(34):17829‐17847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Yamada Y, Ando F, Shimokata H. Association of genetic variants of MAOA and SH2B1 with bone mineral density in community‐dwelling Japanese women. Mol Med Rep. 2008;1(2):269‐274. [PubMed] [Google Scholar]
  • 33. Thaler R, Zwerina J, Rumpler M, et al. Homocysteine induces serum amyloid A3 in osteoblasts via unlocking RGD‐motifs in collagen. FASEB J. 2013;27(2):446‐463. [DOI] [PubMed] [Google Scholar]
  • 34. Shur I, Socher R, Hameiri M, Fried A, Benayahu D. Molecular and cellular characterization of SEL‐OB/SVEP1 in osteogenic cells in vivo and in vitro. J Cell Physiol. 2006;206(2):420‐427. [DOI] [PubMed] [Google Scholar]
  • 35. Gu YC, Talts JF, Gullberg D, Timpl R, Ekblom M. Glucocorticoids down‐regulate the extracellular matrix proteins fibronectin, fibulin‐1 and fibulin‐2 in bone marrow stroma. Eur J Haematol. 2001;67(3):176‐184. [DOI] [PubMed] [Google Scholar]
  • 36. Yu S, Sharma R, Nie D, et al. ADAR1 ablation decreases bone mass by impairing osteoblast function in mice. Gene. 2013;513(1):101‐110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Toyama K, Honmou O, Harada K, et al. Therapeutic benefits of angiogenetic gene‐modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol. 2009;216(1):47‐55. [DOI] [PubMed] [Google Scholar]
  • 38. Cooley MA, Harikrishnan K, Oppel JA, et al. Fibulin‐1 is required for bone formation and Bmp‐2‐mediated induction of Osterix. Bone. 2014;69:30‐38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gu Q, Tian H, Zhang K, et al. Wnt5a/FZD4 mediates the mechanical stretch‐induced osteogenic differentiation of bone mesenchymal stem cells. Cell Physiol Biochem. 2018;48(1):215‐226. [DOI] [PubMed] [Google Scholar]
  • 40. Hodgkinson CP, Naidoo V, Patti KG, et al. Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology. Stem Cells. 2013;31(8):1669‐1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Pu Y, Wang M, Hong Y, Wu Y, Tang Z. Adiponectin promotes human jaw bone marrow mesenchymal stem cell chemotaxis via CXCL1 and CXCL8. J Cell Mol Med. 2017;21(7):1411‐1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Onizuka S, Iwata T, Park SJ, et al. ZBTB16 as a downstream target gene of osterix regulates osteoblastogenesis of human multipotent mesenchymal stromal cells. J Cell Biochem. 2016;117(10):2423‐2434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Sugars RV, Olsson ML, Marchner S, Hultenby K, Wendel M. The glycosylation profile of osteoadherin alters during endochondral bone formation. Bone. 2013;53(2):459‐467. [DOI] [PubMed] [Google Scholar]
  • 44. Madrigal A, Tan L, Zhao Y. Expression regulation and functional analysis of RGS2 and RGS4 in adipogenic and osteogenic differentiation of human mesenchymal stem cells. Biol Res. 2017;50(1):43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt signaling in myogenesis. Trends Cell Biol. 2012;22(11):602‐609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Gao C, Chen G, Romero G, Moschos S, Xu X, Hu J. Induction of Gsk3beta‐beta‐TrCP interaction is required for late phase stabilization of beta‐catenin in canonical Wnt signaling. J Biol Chem. 2014;289(10):7099‐7108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Eastell R, O'Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069. [DOI] [PubMed] [Google Scholar]
  • 48. Kim BJ, Lee YS, Lee SY, et al. Osteoclast‐secreted SLIT3 coordinates bone resorption and formation. J Clin Invest. 2018;128(4):1429‐1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Lee WC, Guntur AR, Long F, Rosen CJ. Energy metabolism of the osteoblast: implications for osteoporosis. Endocr Rev. 2017;38(3):255‐266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121‐145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. van de Peppel J, Strini T, Tilburg J, Westerhoff H, van Wijnen AJ, van Leeuwen JP. Identification of three early phases of cell‐fate determination during osteogenic and adipogenic differentiation by transcription factor dynamics. Stem cell reports. 2017;8(4):947‐960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Kumarapeli AR, Su H, Huang W, et al. Alpha B‐crystallin suppresses pressure overload cardiac hypertrophy. Circ Res. 2008;103(12):1473‐1482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Chis R, Sharma P, Bousette N, et al. alpha‐Crystallin B prevents apoptosis after H2O2 exposure in mouse neonatal cardiomyocytes. Am J Physiol Heart Circ Physiol. 2012;303(8):H967‐978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Dimberg A, Rylova S, Dieterich LC, et al. alphaB‐crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood. 2008;111(4):2015‐2023. [DOI] [PubMed] [Google Scholar]
  • 55. Liu B, Bhat M, Nagaraj RH. AlphaB‐crystallin inhibits glucose‐induced apoptosis in vascular endothelial cells. Biochem Biophys Res Commun. 2004;321(1):254‐258. [DOI] [PubMed] [Google Scholar]
  • 56. Iwaki T, Kume‐Iwaki A, Liem RK, Goldman JE. Alpha B‐crystallin is expressed in non‐lenticular tissues and accumulates in Alexander's disease brain. Cell. 1989;57(1):71‐78. [DOI] [PubMed] [Google Scholar]
  • 57. Liu Y, Zhou Q, Tang M, et al. Upregulation of alphaB‐crystallin expression in the substantia nigra of patients with Parkinson's disease. Neurobiol Aging. 2015;36(4):1686‐1691. [DOI] [PubMed] [Google Scholar]
  • 58. Dammer EB, Lee AK, Duong DM, et al. Quantitative phosphoproteomics of Alzheimer's disease reveals cross‐talk between kinases and small heat shock proteins. Proteomics. 2015;15(2–3):508‐519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Mao YW, Liu JP, Xiang H, Li DW. Human alphaA‐ and alphaB‐crystallins bind to Bax and Bcl‐X(S) to sequester their translocation during staurosporine‐induced apoptosis. Cell Death Differ. 2004;11(5):512‐526. [DOI] [PubMed] [Google Scholar]
  • 60. Kulterer B, Friedl G, Jandrositz A, et al. Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genom. 2007;8:70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Graneli C, Thorfve A, Ruetschi U, et al. Novel markers of osteogenic and adipogenic differentiation of human bone marrow stromal cells identified using a quantitative proteomics approach. Stem Cell Res. 2014;12(1):153‐165. [DOI] [PubMed] [Google Scholar]
  • 62. Iyer S, Ambrogini E, Bartell SM, et al. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013;123(8):3409‐3419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Scholtysek C, Katzenbeisser J, Fu H, et al. PPARbeta/delta governs Wnt signaling and bone turnover. Nat Med. 2013;19(5):608‐613. [DOI] [PubMed] [Google Scholar]
  • 64. Kuci S, Kuci Z, Schafer R, et al. Molecular signature of human bone marrow‐derived mesenchymal stromal cell subsets. Sci Rep. 2019;9:1774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179‐192. [DOI] [PubMed] [Google Scholar]
  • 66. van de Peppel J, Strini T, Tilburg J, et al. Gene expression analyses of the differentiating hMSC into osteoblasts and adipocytes. Gene Expression Omnibus. 2017;GSE80614. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

 

Click here for additional data file. (365.6KB, docx)

Data Availability Statement

The data that support the findings of this study are openly available in GEO database at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80614.66

Articles from Cell Proliferation are provided here courtesy of Wiley

RESOURCES